Logo

Ligand Pharmaceuticals’ Zelsuvmi Receives the US FDA’s Approval for the Treatment of Molluscum Contagiosum

Share this
Ligand Pharmaceuticals

Ligand Pharmaceuticals’ Zelsuvmi Receives the US FDA’s Approval for the Treatment of Molluscum Contagiosum

Shots:

  • Zelsuvmi (berdazimer topical gel, 10.3%) received the US FDA’s approval as a novel drug for the treatment of molluscum infections in adults & pediatric patients aged ≥1yrs. Zelsuvmi is expected to be commercially available in the US by H2’24
  • The company evaluated the safety & effectiveness of the US FDA-approved Zelsuvmi in P-III clinical trials (B-SIMPLE 4) & (B-SIMPLE 2) among patients (n=1,598) with Molluscum Contagiosum that depicted Zelsuvmi’s ability to reduce lesion counts & was well tolerated as QD dosage in patients
  • Zelsuvmi is a nitric oxide (NO) releasing agent that has been attributed to have antiviral properties. With unknown mechanism of action of Zelsuvmi will be used as a tropical treatment in patients above age of 1year (pediatric & adults)

Ref: Ligand Pharmaceuticals | Image: Ligand Pharmaceuticals

Related News:- Palvella Therapeutics Expands Partnership with Ligand Pharmaceuticals to Accelerate P-III development of Qtorin Rapamycin

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions